Last reviewed · How we verify
Carbetocin bolus
Carbetocin is a synthetic oxytocin analogue that binds to oxytocin receptors to stimulate uterine contractions and promote hemostasis.
Carbetocin is a synthetic oxytocin analogue that binds to oxytocin receptors to stimulate uterine contractions and promote hemostasis. Used for Prevention of postpartum hemorrhage following vaginal delivery, Prevention of postpartum hemorrhage following cesarean section.
At a glance
| Generic name | Carbetocin bolus |
|---|---|
| Also known as | Duratocin |
| Sponsor | Ciusss de L'Est de l'Île de Montréal |
| Drug class | Oxytocin receptor agonist |
| Target | Oxytocin receptor (OXTR) |
| Modality | Small molecule |
| Therapeutic area | Obstetrics |
| Phase | FDA-approved |
Mechanism of action
Carbetocin mimics the natural hormone oxytocin by activating oxytocin receptors on uterine smooth muscle, triggering sustained contractions that compress bleeding vessels and reduce postpartum hemorrhage. It has a longer duration of action and more selective receptor binding compared to oxytocin, making it effective at lower doses for prevention and treatment of uterine atony.
Approved indications
- Prevention of postpartum hemorrhage following vaginal delivery
- Prevention of postpartum hemorrhage following cesarean section
Common side effects
- Hypertension
- Tachycardia
- Headache
- Nausea
- Flushing
Key clinical trials
- Prophylactic Regimen of Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative for Primary Prevention of Postpartum Hemorrhage in Intrapartum Cesarean Section Versus Intravenous Carbetocin Alone (NA)
- To Compare the Effects of Oxytocin and Carbetocin on Intraoperative Hemodynamic Changes in Cesarean Section Surgeries. (NA)
- Effects of Carbetocin and Oxytocin Used in Cesarean Sections on Postoperative Pain
- Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium (NA)
- Comparing Tranexamic Acid Versus Ecbolics in Preventing Hemorrhage During and After Cesarean Section (NA)
- Efficacy of Carbetocin in Prevention of Postpartum Hemorrhage in Obese Versus Non Obese Women (PHASE1, PHASE2)
- Carbetocin in the Prevention of Primary Postpartum Haemorrhage
- Carbetocin Versus Syntocinon for Prevention of Postpartum Hemorrhage in Cardiac Patients Undergoing Caesarean Section (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carbetocin bolus CI brief — competitive landscape report
- Carbetocin bolus updates RSS · CI watch RSS
- Ciusss de L'Est de l'Île de Montréal portfolio CI